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Glutamate (Glu) and γ-aminobutyric acid (GABA) are major neurotransmitters in the mam-
malian brain which regulate brain development at molecular, cellular, and systems level.
Sedative, anesthetic, and antiepileptic drugs (AEDs) interact with glutamate and GABA
receptors to produce their desired effects.The question is posed whether such interference
with glutamatergic and GABAergic neurotransmission may exert undesired, and perhaps
even detrimental effects on human brain development. Preclinical research in rodents and
non-human primates has provided extensive evidence that sedative, anesthetic, and AEDs
can trigger suicide of neurons and oligodendroglia, suppress neurogenesis, and inhibit
normal synapse development and sculpting. Behavioral correlates in rodents and non-
human primates consist of long-lasting cognitive impairment. Retrospective clinical studies
in humans exposed to anesthetics or AEDs in utero, during infancy or early childhood have
delivered conflicting but concerning results in terms of a correlation between drug exposure
and impaired neurodevelopmental outcomes. Prospective studies are currently ongoing.
This review provides a short overview of the current state of knowledge on this topic.
Keywords: glutamate,N -methyl-D-aspartate, GABA, apoptosis, neurogenesis, synaptogenesis, neurodevelopmen-
tal disorder
INTRODUCTION
Short- and long-term deleterious effects, resulting from any inter-
ference with normal brain development, differ depending on the
nature of interference, and the timing of the insult (Rodier, 1980).
Despite variations in the rates of brain growth among mammals,
comparisons of brain development between species are possible
(Passingham, 1985; Bayer et al., 1993). Developmental ages are
comparable when anatomical features and histological landmarks
are similar in appearance in two species despite differences in
chronological ages (Bayer et al., 1993). In the central nervous sys-
tem, structures are built by cell proliferation, migration, and a
sequence of steps called differentiation. Normal function requires
a specific number of cells with the proper characteristics in the
correct location (Rodier, 1980). Cell migration enables that neu-
rons reach their final location where they establish physical contact
between themselves and construct complex circuits (Rodier,1994).
Connections occur via the process of synaptogenesis. The devel-
opmental period of synaptogenesis is critical for the formation
of the basic circuitry of the nervous system, although neurons
are able to form new synapses throughout life (Rodier, 1995).
Neurotransmitters modulate proliferation of neural stem cells,
neuroblasts, and glioblasts, regulate migration and induce differ-
entiation (Emerit et al., 1992; Retz et al., 1996; Levitt et al., 1997;
Nguyen et al., 2001).
Neurogenesis produces about twice as many neurons in a given
structure as the number of neurons that survive into adulthood.
Excessive cells are eliminated by apoptosis or programmed cell
death (Johnson and Deckwerth, 1993). Apoptosis is regulated by
growth factors and cytokines, as well as by neurotransmitters and
is executed by a number of intracellular proteins (Henderson,
1996; Kroemer et al., 2009). Any compound that interferes with
these processes may trigger apoptotic degeneration of neurons that
would not have otherwise been deleted from the developing brain,
or may promote survival of unnecessary cells (Webb et al., 2001).
Pruning, defined as a loss of synapses, also occurs physiologically
in the developing brain. Such trimming of connections occurs late
in childhood and adolescence (Webb et al., 2001).
N -METHYL-D-ASPARTATE (NMDA) ANTAGONISTS AND
GABA-AGONISTS ARE NEUROTOXINS FOR THE DEVELOPING
BRAIN
A decade ago, it was reported that antagonists of the NMDA sub-
type of glutamate receptors cause widespread apoptotic neurode-
generation in the developing rat brain (Ikonomidou et al., 1999).
NMDA receptors undergo a period of hypersensitivity through
increased expression of specific receptor subunits (McDonald
et al., 1988; Ikonomidou et al., 1989; Miyamoto et al., 2001).
During this period, which extends from late fetal life to the first
2 weeks after birth in the rat, blockade of NMDA receptors with
dizocilpine [(+)MK801], phencyclidine, ketamine, or 3-((6)-2-
carboxypiperazin-4-yl)propyl-1-phosphonate (CPP) for a period
of hours triggers widespread apoptotic neurodegeneration in the
brain (Ikonomidou et al., 1999) and may lead to detrimental long-
term effects (Behar et al., 1999; Popke et al., 2001). Treatment of
infant rats with intraperitoneal injections of (+)MK801 resulted
in a marked increase of degenerating neurons from threefold in the
hypothalamus to 39-fold in the laterodorsal thalamus, when exam-
ined at 24 h by appropriate staining techniques (Ikonomidou et al.,
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1999). The form of cell death was found to be ultrastructurally
identical with apoptotic cell death (Ikonomidou et al., 1999). Dif-
ferent brain regions display different age-dependent vulnerability
profiles to NMDA receptor blockade, leading to distinct patterns
of neuronal loss, depending on the timing of exposure. MK801
was shown to increase apoptosis either in vivo (Hsu et al., 2000),
in motor neurons of a chick embryo preparation (Hsu et al., 2000),
or in cultured neurons (Terro et al., 2000).
Further preclinical research revealed that a robust apoptotic
response can also be triggered by agents (benzodiazepines and
barbiturates) that mimic or potentiate the action of GABA at
GABAA receptors (Ikonomidou et al., 2000). Benzodiazepines and
barbiturates, in a dose-dependent manner, triggered widespread
cell death in the infant rat brain, which by ultrastructural analy-
sis was apoptotic. The pattern of degeneration was similar for
each GABAergic agent, but this pattern differed in several major
respects from that induced by NMDA antagonists (Ikonomidou
et al., 2000).
Evidence that ethanol, the most widely abused drug in the
world, has NMDA antagonist and GABAA-agonist properties
(Hoffman et al., 1989; White et al., 1990; Lovinger and White,
1991; Chandler et al., 1999) prompted evaluation of its ability
to mimic the proapoptotic effects of other NMDA antagonists
and GABAA agonists. Transplacental ethanol exposure of the
human fetus in utero can cause craniofacial anomalies, micro-
cephaly, mental retardation, and neurobehavioral disturbances
(Jones and Smith, 1973, 1975; Sulik et al., 1981; Stratton et al.,
1996; Faingold et al., 1998). The fetotoxic effects of ethanol can
also manifest as a partial syndrome comprised largely of neu-
robehavioral disturbances, without craniofacial malformations,
referred to as fetal alcohol effects (FAE) or alcohol related neu-
rodevelopmental disorder (ARND; Barr and Streissguth, 2001).
During the brain growth spurt period, brief exposure to ethanol
can trigger widespread apoptosis in the in vivo mammalian brain
(Ikonomidou et al., 1999, 2000; Dikranian et al., 2001). While other
mechanisms may play a role, the ability of ethanol to induce wide-
spread apoptotic neurodegeneration throughout the forebrain,
provides a more likely explanation than has been available pre-
viously for the reduced brain mass and lifelong neurobehavioral
disturbances associated with the human fetal alcohol spectrum
disorders (FASD; Ikonomidou et al., 1999, 2000; Dikranian et al.,
2001; Olney et al., 2002a,b).
SEDATIVE, ANESTHETIC, AND ANTIEPILEPTIC DRUGS CAUSE
NEURONAL APOPTOSIS IN THE DEVELOPING BRAIN
Sedative, anesthetic, and antiepileptic drugs (AEDs), routinely
used in obstetric and pediatric medicine, trigger widespread
apoptotic neurodegeneration throughout the developing brain
when administered to immature rodents during the brain growth
spurt (Mennerick et al., 1998; Ikonomidou et al., 2001; Jevtovic-
Todorovic et al., 2003; Olney et al., 2004; Wang et al., 2006). Since
the comparable period in humans extends from the sixth month of
pregnancy to several years after birth (Dobbing and Sands, 1979,
1993), the hypothesis is formulated that there is a period in pre-
and postnatal human development that lasts for several years, dur-
ing which immature human neurons might be prone to commit
suicide if exposed to sedative, anesthetic, or AEDs.
Neurotoxic effects of AEDs have been systematically studied in
infant rodents (Bittigau et al., 2002; Glier et al., 2004; Manthey
et al., 2005; Katz et al., 2007; Kim et al., 2007; Ikonomidou and
Turski, 2010; Forcelli et al., 2011). The majority of them may cause
apoptotic neurodegeneration in the developing rat brain at doses
and plasma concentrations relevant for anticonvulsant treatment
in humans. Apoptogenic effects were described for phenytoin,
phenobarbital, diazepam, clonazepam, valproate, and vigabatrin
(Bittigau et al., 2002). It was also determined that the apoptotic
response to AEDs differs as a function of developmental age (Bit-
tigau et al., 2002). Interestingly, topiramate elicited a neurotoxic
effect in infant rat brain beginning at a dose of 50 mg/kg, which is
above the reported effective anticonvulsant doses in infant rodent
seizure models (Glier et al., 2004), suggesting a rather beneficial
profile. Levetiracetam showed no neurotoxicity in the infant rat
brain at all doses tested (Manthey et al., 2005).
MECHANISMS IMPLICATED IN NEUROTOXICITY OF
SEDATIVE, ANESTHETIC, AND ANTIEPILEPTIC DRUGS
Changes in synthesis of neurotrophins, i.e., brain derived neu-
rotrophic factor, neurotrophins three and four as well as reduced
levels of the active phosphorylated forms of extracellular sig-
nal regulated kinase (ERK1/2) and protein kinase B (AKT),
were shown to partly underlie neurotoxicity (Bittigau et al.,
2002; Hansen et al., 2004). Interestingly, 17β-estradiol counter-
acted inactivation of the ERK1/2 and AKT pathways and pro-
tected against neurotoxicity of some AEDs (Bittigau et al., 2002;
Asimiadou et al., 2005).
The cell death process is Bax-dependent (Young et al., 2003)
and involves decreased expression of phosphorylated extracellular
signal regulated protein kinase (pERK; Young et al., 2008; Straiko
et al., 2009; Sanders et al., 2010), and down regulation of BclxL
(Yon et al., 2005; Sanders et al., 2010), mitochondrial injury and
extra-mitochondrial leakage of cytochrome c (Young et al., 2003;
Yon et al., 2005). This is followed by a sequence of changes culmi-
nating in activation of caspase-3 (Olney et al., 2002a,b). Studies
using caspase-3 knockout mice suggest that commitment to cell
death occurs before the caspase-3 activation step (Young et al.,
2005), and this has led to the use of activated caspase-3 (AC3)
immunohistochemistry as a standard means of mapping and
quantifying neurons that undergo apoptotic neurodegeneration
following exposure to apoptogenic drugs.
Involvement of endocannabinoids in the neurotoxic action
of compounds interfering with NMDA receptors or GABAA
receptors has been demonstrated. Administration of ∆9-
tetrahydrocannabinol, the principal psychoactive cannabinoid of
marijuana, markedly enhanced proapoptotic properties of pheno-
barbital and MK801 in infant rats. Infant CB1 receptor knockout
mice were less susceptible to the neurotoxic effect of ethanol. Fur-
thermore, the CB1 receptor antagonist SR141716A ameliorated
neurotoxicity of ethanol (Hansen et al., 2008).
NEUROPROTECTION WITH LITHIUM
It has been observed that alcohol, anesthetic drugs, and AEDs
have an important property in common – all drugs in each cat-
egory that have been tested, rapidly suppress phosphorylation
of extracellular signal regulated kinases (ERK 1 and 2), which
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are known to regulate cell survival in the developing brain.
This is well in advance of caspase-3 activation, which begins
to become detectable at 2–3 h after apoptogenic drug adminis-
tration (Olney et al., 2002a,b). In the developing mouse brain,
lithium significantly increased ERK phosphorylation, and EtOH’s
suppressant action on pERK was totally abolished when lithium
was administered together with EtOH. The same effect was seen
when lithium was administered together with anesthetic drugs
(Straiko et al., 2009). Lithium also powerfully protected against
the neurotoxic action of alcohol (Young et al., 2008) or anes-
thetic drugs, including propofol and ketamine (Straiko et al.,
2009).
NEUROGENESIS
Neurogenesis in the central nervous system occurs mainly prena-
taly in mammals, but continues to take place throughout life in
restricted regions. Areas where substantial neurogenesis is found
during the early postnatal period in rats and mice include the
subventricular zone of the lateral ventricles, the cerebellum, the
olfactory bulbs, and the subgranular zone of the hippocampal den-
tate gyrus (Cameron and McKay, 1999; Götz and Huttner, 2005).
Enhanced neurogenesis has been associated with improved spa-
tial memory performance in rodents (Kempermann et al., 1997,
1998).
Interference with neurotransmitters has been shown to influ-
ence neurogenesis in adulthood (Ge et al., 2006; Nacher and
McEwan, 2006). However, knowledge on the influence of seda-
tive and anticonvulsant drugs on early postnatal neurogenesis is
limited.
In a recent study, the question of whether or not drugs that
induce neuroapoptosis in the developing rodent brain also impair
neurogenesis was addressed (Stefovska et al., 2008). The NMDA
antagonist MK801, and the GABAA agonists phenobarbital and
diazepam were administered to infant rats; cell proliferation and
neurogenesis were studied in the brain. Neurogenesis was quan-
tified in the dentate gyrus on postnatal day 15, following treat-
ment with MK801 or with phenobarbital on postnatal days 6–
10. MK801, phenobarbital, and diazepam reduced numbers of
newly born cells in the brain. In the dentate gyrus, many of
the newly formed cells differentiated toward a neuronal phe-
notype. Phenobarbital and MK801 significantly reduced num-
bers of new neurons in that structure. At the age of 6 months,
phenobarbital-treated rats had fewer neurons in the dentate
gyrus and performed worse than saline-treated littermates in
water maze learning and memory task. These findings show
that blockade of NMDA receptor-mediated excitation, as well
as enhancement of GABAA-receptor activation, impair cell pro-
liferation, and inhibit neurogenesis in the immature rat brain
(Stefovska et al., 2008). Comparable results have been reported
by other groups (Chen et al., 2009; Shi et al., 2010; Fan et al.,
2012).
ANESTHESIA-INDUCED IMPAIRMENT OF SYNAPSE
DEVELOPMENT AND REMODELING AND CYTOSKELETON
FORMATION
The detrimental effect of general anesthetics on synaptogenesis
is age-dependent and most severe if the exposure occurs at the
peak of synaptogenesis (Yon et al., 2005). General anesthetics
administered to rats at postnatal day 7 cause severe, long-
lasting functional and ultrastructural abnormalities of developing
synapses in the hippocampus (Lunardi et al., 2010). No changes
in synaptic lengths, the thickness of postsynaptic densities, or the
number of presynaptic vesicles have been found, but significant
decreases in synapse volumetric densities, paucity of multiple
synaptic boutons, and long-lasting decreases in the strength of
inhibitory synaptic neurotransmission were reported (Lunardi
et al., 2010, 2011).
In a recent study it was shown that exposure of mice to gen-
eral anesthesia at the peak of synaptogenesis causes significant
reductions in dendritic filopodial spines and synapse formation in
hippocampal neurons (Head et al., 2009). Briner et al. (2010) have
found that exposure of mice to general anesthesia on postnatal
day 16 results in a significant increase in the density of dendritic
spines in the basal and apical dendrites in pyramidal neurons of
the prefrontal cortex. These results indicate strong age-dependent
vulnerability of synaptic spines and boutons during early stages of
brain development.
The actin cytoskeleton determines neuronal and glial mor-
phology and function. Lunardi et al. (2011) and others (Lemkuil
et al., 2011) explored whether general anesthesia modulates
those signaling pathways. Immature primary glia in culture were
exposed to an inhalational anesthetic, isoflurane. This led to
profound disruption of actin cytoskeleton organization, trig-
gered by significant disruption of the Ras homolog gene family
member A (RhoA)–myosin light chain (MLC) signaling path-
way (Lunardi et al., 2011). RhoA is the most influential member
of a family of small GTPases (Bishop and Hall, 2000). RhoA
functions as a molecular switch, cycling between an inactive
GDP-bound state and an active GTP-bound state, and regu-
lates the phosphorylation of MLC proteins (MLC-P), which, in
turn, promote organization of the actin cytoskeleton in actin
stress fibers (ASFs), and the formation of focal adhesions. It
appears that isoflurane causes severe disruption of actin cytoskele-
tal sculpting by modulating the RhoA signaling pathway, that
is, by downregulating activated RhoA and MLC-P. This ulti-
mately leads to impairment of astrocyte morphological differ-
entiation and maturation (Lunardi et al., 2011). Similar disrup-
tion of the actin cytoskeleton was observed when primary glia
were exposed to alcohol (Guasch et al., 2003; Minambres et al.,
2006).
Immature neurons appear to be vulnerable to isoflurane-
induced disruption of the actin cytoskeleton as well. Lemkuil
et al. (2011) have shown that relatively brief exposure to isoflurane
(up to 120 min) resulted in significant cytoskeletal depolymeriza-
tion and disorganization. They report that actin depolymerization
is brain derived neurotrophic factor/p75 neurotrophin receptor-
mediated, and relies on upregulation of activated RhoA, as shown
in immature astroglia. This suggests that the isoflurane-induced
impairment of actin cytoskeletal sculpting observed in both imma-
ture neurons and glial cells is initiated by two apparently opposite
effects on the activated RhoA protein. The result is impairment of
proper neurite growth (Lemkuil et al., 2011) and glial process for-
mation (Lunardi et al., 2011), necessary for neuron–neuron and
neuron–glia interactions.
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ANESTHESIA-INDUCED IMPAIRMENT OF GLIAL
MATURATION AND GROWTH
Given that neuronal well-being and development depend on the
integrity and proper functioning of astroglia (Ullian et al., 1991;
Barres,2008), the most abundant group of glial cells, it is important
to understand whether and how anesthesia may disturb astroglia
development. Exposure of cultured immature astroglia to isoflu-
rane causes significant impairment of their growth and postpone
timely astroglial morphological transformation. Isoflurane causes
significant disturbances in ASF formation and the content of pax-
illin, a focal adhesion protein that is linked to ASFs and enables
anchoring to the extracellular matrix, and cytoskeletal organi-
zation (Lunardi et al., 2011). This hinders the formation of an
organized glial network.
Apoptotic cell death is not a significant component of isoflu-
rane toxicity in astroglia (Lunardi et al., 2011). However, recently
Brambrink et al. (2012b) reported that isoflurane causes signifi-
cant apoptotic changes in developing oligodendroglia in vivo in
the non-human primate brain. Thus, it is reasonable to propose
that general anesthesia is most likely detrimental to glial devel-
opment also, and that it exerts its detrimental effects via different
mechanisms, that are unique to each subpopulation of glial cells.
EVIDENCE FOR ADVERSE EFFECTS OF ANESTHETICS IN
HUMANS AND NON-HUMAN PRIMATES
Studies conducted by the National Center for Toxicology Research
(NCTR) of the Food and Drug Administration (FDA) have
demonstrated that exposure to ketamine – the prototypical NMDA
receptor antagonist – resulted in increased neuronal cell death in
non-human primates. Doses of ketamine which produced a light
surgical plane of anesthesia for either 9 or 24 h resulted in neu-
roapoptosis in 5-day-old rhesus monkeys. Neuroapoptosis in the
brain of the fetus was also evident when pregnant rhesus mon-
keys were exposed to ketamine for 24 h on day 122 of gestation
(equivalent to the third trimester of human pregnancy), but no
neuroapoptosis was noted following administration of ketamine
on postnatal day 35 (Slikker et al., 2007). Neuroapoptosis has also
been demonstrated in primates who were given isoflurane (pre-
dominantly a GABAergic agent) on postnatal day 6 (Brambrink
et al., 2012a). The FDA and others are currently conducting stud-
ies in animals to address the neurocognitive and neurobehavioral
effects of anesthetic-induced apoptosis.
An operant test battery is used to evaluate the cognitive func-
tion of rhesus monkeys exposed to a dose of ketamine sufficient to
produce a light surgical plane of anesthesia for 24 h on postnatal
day 5 or 6. Compared with controls,ketamine-treated animals have
lower training scores for at least 10 months after the administration
of ketamine (Paule et al., 2011).
It is not known how the data from rodents or primates translate
to humans, but such findings raise questions that require further
studies.
A retrospective cohort analysis followed a birth cohort of 383
human children who underwent inguinal hernia repair during the
first 3 years of life, and compared them with 5050 children in a
control sample who had undergone no hernia repair before the
age of three (DiMaggio et al., 2009). The children who under-
went hernia repair were twice as likely to be given a diagnosis
of a developmental or behavioral disorder. A population-based,
retrospective, birth cohort study examined the educational and
medical records of children who were exposed to a single anes-
thetic (n= 449), two anesthetics (n= 100), or more (n= 44). No
increased risk of learning disabilities was found with a single anes-
thetic but, an increasing risk of learning disabilities was associated
with two or more anesthetics. The risk of learning disabilities also
increased with greater cumulative exposure to anesthesia (Wilder
et al., 2009).
At present, there is not enough information to draw any firm
conclusions regarding an association between anesthetic exposure
and subsequent learning disabilities, and additional studies are
warranted.
CLINICAL EVIDENCE FOR ADVERSE OUTCOMES FOLLOWING
PRENATAL OR EARLY CHILDHOOD EXPOSURE TO AEDs IN
HUMANS
Antiepileptic drugs are among the most common causes of fetal
malformations. These include neural tube defects, orofacial clefts
and digital anomalies, growth retardation, developmental delay,
and microcephaly (Speidel and Meadow, 1972; Strickler et al.,
1985; Jones et al., 1989; Buehler et al., 1990; Zahn, 1998; Holmes
et al., 2001).
It has also been shown that AEDs may have adverse effects on
human intellect when given to treat seizures in pregnant women,
infants, and toddlers. Long-lasting neurobehavioral effects in
humans following in utero exposure to phenobarbital, such as
impaired cognitive development and lower IQ scores (Reinisch
et al., 1995), have been reported. Valproic acid is a clear animal and
human teratogen (Winter et al., 1997; Holmes et al., 2001; Wyszyn-
ski et al., 2005). The nervous system appears to be very sensitive to
the developmental toxicity of valproic acid. Neural tube defects,
specifically spina bifida, occur at a high rate upon in utero exposure
to this compound (Lindhout and Schmidt, 1986). Carbamazepine
has been found to be teratogenic in humans, and the pattern
of malformations (facial dysmorphic features, microcephaly, and
growth retardation) resembles that of other anticonvulsants (Jones
et al., 1989; Matalon et al., 2002). The fetal hydantoin syndrome in
humans is characterized by facial dysmorphologies, growth retar-
dation and other anomalies, and similar effects have also been
seen in rodents (Finnell and Chernoff, 1984; Finnell et al., 2002).
Microcephaly, learning disabilities, and decreased IQ scores have
also been reported in humans (Adams et al., 1990; van Overloop
et al., 1992; Dessens et al., 2000).
The majority of studies investigating the effects of prenatal
AED exposure were performed in children below age five. In many
studies, a trend toward lower developmental scores was reported,
although in a few studies no adverse effects could be shown (Rovet
et al., 1995). In a longitudinal study, children exposed to carba-
mazepine and phenytoin had lower developmental and language
scores, compared to controls. In children receiving carbamazepine,
a deficit in language development was not evident until an age
beyond 3 years, suggesting that specific cognitive deficits may first
become apparent when the child is older (Adab et al., 2001).
Inconsistent results have also been obtained in studies that have
investigated the long-term effects of AED exposure in children
older than 5 years (Hanson et al., 1976; Gaily et al., 1988; Dessens
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et al., 2000; Mawer et al., 2002). Some studies have reported specific
cognitive deficits in visuo-spatial functioning (Hanson et al., 1976;
van der Pol et al., 1991), spelling and linguistic abilities (Leavitt
et al., 1982; Scolnick et al., 1994; Adab et al., 2001).
Intrauterine exposure to phenytoin, phenobarbital, polyther-
apy, valproate, and carbamazepine is associated with lower intel-
lectual functioning (Leavitt et al., 1982; Lösche et al., 1994; Scolnick
et al., 1994; Vinten et al., 2005). Carbamazepine appears to be
the least developmentally neurotoxic compound among the major
AEDs. Although in one study, mild mental retardation has been
reported in children exposed in utero to carbamazepine (Ornoy
and Cohen, 1996), no neurologic, or IQ differences were found
by other investigators (van der Pol et al., 1991; Scolnick et al.,
1994).
In humans, in utero exposure to valproic acid has been asso-
ciated with developmental delay, mental retardation, cognitive
impairment, and other behavioral deficits (Sulzbacher et al., 1999;
Thorp et al., 1999). In a retrospective study exploring neu-
ropsychological effects of exposure to anticonvulsant medication
in utero, children exposed in utero to valproate had a significantly
lower IQ when compare to children exposed to other AEDs, or
not exposed at all. The same children were more likely to have an
IQ below 69 and more likely to have memory impairment when
compared to other groups (Vinten et al., 2005).
In addition, postnatal exposure to AEDs during the first years
of life may be harmful for cognitive development. In several stud-
ies it was shown that therapy with barbiturates during the first
3 years of life may cause cognitive impairment that persists into
adulthood (Diaz et al., 1977; Yanai et al., 1989; Farwell et al., 1990;
Reinisch et al., 1995).
Meador et al. (2009) conducted a prospective clinical study of
the impact of in utero exposure to AED on cognitive abilities. At
3 years of age, children who had been exposed to valproate in utero
had significantly lower IQ scores than those who had been exposed
to other AEDs. After adjustment for maternal IQ, maternal age,
AED dose, gestational age at birth, and maternal preconception
use of folate, the mean IQ was 101 for children exposed to lamot-
rigine, 99 for those exposed to phenytoin, 98 for those exposed to
carbamazepine, and 92 for those exposed to valproate. On aver-
age, children exposed to valproate had an IQ score nine points
lower than the score of those exposed to lamotrigine, seven points
lower than the score of those exposed to phenytoin, and six points
lower than the score of those exposed to carbamazepine. They
concluded that in utero exposure to valproate, as compared with
other commonly used AEDs, is associated with an increased risk of
impaired cognitive function at 3 years of age. This finding supports
a recommendation that valproate not be used as a first-choice drug
in women of childbearing potential.
Morphological changes in the brains of subjects exposed
in utero to AEDs have also been analyzed. A group of healthy young
adults with prenatal AED exposure (PAE) and a group of age-
matched unexposed healthy controls were subjected to magnetic
resonance imaging (MRI) of the brain and structural differences
between the two groups were studied by means of voxel based
morphometry (Ikonomidou et al., 2007).
Regional decreases of gray matter volumes were found in PAE
subjects in the area of the lentiform nucleus, including both
pallidum and putamen bilaterally, and the hypothalamus. Thus,
prenatal exposure to AEDs causes subtle morphological changes
in gray matter of the human brain, consisting of lower gray matter
volumes in the basal ganglia and the hypothalamus.
CONCLUSION
The experimental data reviewed provide compelling evidence that
sedative, anesthetic, and AEDs may alter normal brain develop-
ment by influencing cell proliferation, neurogenesis, migration,
programmed cell death, synaptogenesis, synaptic plasticity, and
possibly myelination in the developing brain. A critical period of
high vulnerability of the brain to AEDs is the brain growth spurt
period.
These findings raise concerns regarding current clinical prac-
tice of employing these drugs to pregnant women, infants, and
children. They call for the design of novel sedative, anesthetic,
and AEDs, adjunctive neuroprotective therapies, and generation
of new clinical data by means of well designed clinical tri-
als to guide clinical practice. The findings that β-estradiol and
lithium ameliorated apoptosis in experimental animal models is
encouraging in that respect, and may lead to new therapeutic
avenues that will allow to prevent neurotoxicity of sedatives and
anesthetics.
Of note is also that experimental studies demonstrated favor-
able profile for carbamazepine and lamotrigine. Topiramate is an
AED with a favorable therapeutic index in terms of the separa-
tion between anticonvulsant activity and neurotoxic/proapoptotic
effects in the developing rat brain (Glier et al., 2004). Even more
encouraging was the finding that levetiracetam does not demon-
strate a proapoptotic effect (Manthey et al., 2005). Thus, there is
hope that it will be possible to design age-specific antiepileptic
therapies and at the same time avoid or minimize neurotoxic side
effects in the vulnerable age groups.
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